Annual EBITDA
-$7.46 M
+$10.15 M+57.65%
December 31, 2023
Summary
- As of February 12, 2025, GLMD annual EBITDA is -$7.46 million, with the most recent change of +$10.15 million (+57.65%) on December 31, 2023.
- During the last 3 years, GLMD annual EBITDA has risen by +$22.71 million (+75.27%).
- GLMD annual EBITDA is now -138.22% below its all-time high of -$3.13 million, reached on December 31, 2012.
Performance
GLMD EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$2.01 M
-$863.00 K-75.17%
September 30, 2024
Summary
- As of February 12, 2025, GLMD quarterly EBITDA is -$2.01 million, with the most recent change of -$863.00 thousand (-75.17%) on September 30, 2024.
- Over the past year, GLMD quarterly EBITDA has dropped by -$551.00 thousand (-37.74%).
- GLMD quarterly EBITDA is now -239.70% below its all-time high of -$592.00 thousand, reached on March 31, 2013.
Performance
GLMD Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$6.70 M
-$551.00 K-8.97%
September 30, 2024
Summary
- As of February 12, 2025, GLMD TTM EBITDA is -$6.70 million, with the most recent change of -$551.00 thousand (-8.97%) on September 30, 2024.
- Over the past year, GLMD TTM EBITDA has increased by +$1.06 million (+13.67%).
- GLMD TTM EBITDA is now -1031.08% below its all-time high of -$592.00 thousand, reached on March 31, 2013.
Performance
GLMD TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
GLMD EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +57.6% | -37.7% | +13.7% |
| 3 y3 years | +75.3% | -37.7% | +13.7% |
| 5 y5 years | +27.8% | -37.7% | +13.7% |
GLMD EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +77.3% | -75.2% | +73.1% | -9.0% | +79.6% |
| 5 y | 5-year | at high | +77.3% | -75.2% | +80.5% | -9.0% | +81.2% |
| alltime | all time | -138.2% | +77.3% | -239.7% | +83.7% | -1031.1% | +81.2% |
Galmed Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$2.01 M(+75.2%) | -$6.70 M(+9.0%) |
| Jun 2024 | - | -$1.15 M(-17.5%) | -$6.14 M(-10.4%) |
| Mar 2024 | - | -$1.39 M(-35.1%) | -$6.86 M(-8.1%) |
| Dec 2023 | -$7.46 M(-57.6%) | -$2.15 M(+46.9%) | -$7.46 M(-3.8%) |
| Sep 2023 | - | -$1.46 M(-21.6%) | -$7.76 M(-33.5%) |
| Jun 2023 | - | -$1.86 M(-6.6%) | -$11.67 M(-13.7%) |
| Mar 2023 | - | -$1.99 M(-18.3%) | -$13.53 M(-23.2%) |
| Dec 2022 | -$17.62 M(-46.4%) | -$2.44 M(-54.6%) | -$17.62 M(-22.3%) |
| Sep 2022 | - | -$5.37 M(+44.4%) | -$22.66 M(-9.8%) |
| Jun 2022 | - | -$3.72 M(-38.8%) | -$25.12 M(-15.7%) |
| Mar 2022 | - | -$6.08 M(-18.7%) | -$29.80 M(-9.3%) |
| Dec 2021 | -$32.84 M(+8.8%) | -$7.48 M(-4.5%) | -$32.84 M(-8.0%) |
| Sep 2021 | - | -$7.83 M(-6.8%) | -$35.69 M(+0.7%) |
| Jun 2021 | - | -$8.40 M(-7.9%) | -$35.44 M(+7.9%) |
| Mar 2021 | - | -$9.12 M(-11.7%) | -$32.84 M(+8.8%) |
| Dec 2020 | -$30.17 M(+35.0%) | -$10.33 M(+36.3%) | -$30.17 M(+6.0%) |
| Sep 2020 | - | -$7.58 M(+30.5%) | -$28.46 M(+10.0%) |
| Jun 2020 | - | -$5.81 M(-10.0%) | -$25.88 M(+4.5%) |
| Mar 2020 | - | -$6.45 M(-25.2%) | -$24.76 M(+10.8%) |
| Dec 2019 | -$22.34 M(+116.3%) | -$8.62 M(+72.5%) | -$22.34 M(+25.5%) |
| Sep 2019 | - | -$5.00 M(+6.5%) | -$17.80 M(+28.6%) |
| Jun 2019 | - | -$4.69 M(+16.4%) | -$13.84 M(+16.7%) |
| Mar 2019 | - | -$4.03 M(-1.1%) | -$11.86 M(+14.8%) |
| Dec 2018 | -$10.33 M | -$4.08 M(+293.0%) | -$10.33 M(+5.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$1.04 M(-61.8%) | -$9.84 M(-14.4%) |
| Jun 2018 | - | -$2.72 M(+8.6%) | -$11.50 M(+0.7%) |
| Mar 2018 | - | -$2.50 M(-30.3%) | -$11.42 M(-5.8%) |
| Dec 2017 | -$12.13 M(-27.5%) | -$3.58 M(+33.0%) | -$12.13 M(-8.4%) |
| Sep 2017 | - | -$2.69 M(+2.0%) | -$13.24 M(-7.4%) |
| Jun 2017 | - | -$2.64 M(-17.6%) | -$14.30 M(-9.8%) |
| Mar 2017 | - | -$3.20 M(-31.9%) | -$15.85 M(-5.2%) |
| Dec 2016 | -$16.71 M(+54.4%) | -$4.70 M(+25.3%) | -$16.71 M(+9.0%) |
| Sep 2016 | - | -$3.75 M(-10.4%) | -$15.34 M(+9.1%) |
| Jun 2016 | - | -$4.19 M(+2.8%) | -$14.06 M(+13.5%) |
| Mar 2016 | - | -$4.07 M(+22.4%) | -$12.39 M(+14.5%) |
| Dec 2015 | -$10.82 M(+18.5%) | -$3.33 M(+34.3%) | -$10.82 M(+13.3%) |
| Sep 2015 | - | -$2.48 M(-1.6%) | -$9.55 M(-6.9%) |
| Jun 2015 | - | -$2.52 M(+0.7%) | -$10.26 M(+8.0%) |
| Mar 2015 | - | -$2.50 M(+21.8%) | -$9.50 M(+4.0%) |
| Dec 2014 | -$9.13 M(-37.3%) | -$2.05 M(-35.6%) | -$9.13 M(-53.0%) |
| Sep 2014 | - | -$3.19 M(+80.9%) | -$19.43 M(+14.9%) |
| Jun 2014 | - | -$1.76 M(-17.4%) | -$16.91 M(+5.1%) |
| Mar 2014 | - | -$2.13 M(-82.7%) | -$16.10 M(+10.6%) |
| Dec 2013 | -$14.56 M(+364.8%) | -$12.36 M(+1763.5%) | -$14.56 M(+560.8%) |
| Sep 2013 | - | -$663.00 K(-30.1%) | -$2.20 M(+43.1%) |
| Jun 2013 | - | -$948.00 K(+60.1%) | -$1.54 M(+160.1%) |
| Mar 2013 | - | -$592.00 K | -$592.00 K |
| Dec 2012 | -$3.13 M | - | - |
FAQ
- What is Galmed Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Galmed Pharmaceuticals?
- What is Galmed Pharmaceuticals annual EBITDA year-on-year change?
- What is Galmed Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Galmed Pharmaceuticals?
- What is Galmed Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Galmed Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Galmed Pharmaceuticals?
- What is Galmed Pharmaceuticals TTM EBITDA year-on-year change?
What is Galmed Pharmaceuticals annual EBITDA?
The current annual EBITDA of GLMD is -$7.46 M
What is the all time high annual EBITDA for Galmed Pharmaceuticals?
Galmed Pharmaceuticals all-time high annual EBITDA is -$3.13 M
What is Galmed Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, GLMD annual EBITDA has changed by +$10.15 M (+57.65%)
What is Galmed Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of GLMD is -$2.01 M
What is the all time high quarterly EBITDA for Galmed Pharmaceuticals?
Galmed Pharmaceuticals all-time high quarterly EBITDA is -$592.00 K
What is Galmed Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, GLMD quarterly EBITDA has changed by -$551.00 K (-37.74%)
What is Galmed Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of GLMD is -$6.70 M
What is the all time high TTM EBITDA for Galmed Pharmaceuticals?
Galmed Pharmaceuticals all-time high TTM EBITDA is -$592.00 K
What is Galmed Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, GLMD TTM EBITDA has changed by +$1.06 M (+13.67%)